Celgene Corp. (CELG)

95.28
0.54 0.57
NASDAQ : Health Technology
Prev Close 94.74
Open 94.76
Day Low/High 94.72 / 95.44
52 Wk Low/High 58.59 / 98.97
Volume 710.77K
Avg Volume 4.16M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 66.13B
EPS 5.70
P/E Ratio 12.78
Div & Yield N.A. (N.A)

Latest News

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

A Solid Start for the Market

We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

The Real Money Post Industrial Average Gains More Ground in February

The Real Money Post Industrial Average Gains More Ground in February

However, the RMPIA did not see as much improvement last month as some other market indices.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

RMPIA soared 9.9% for the month, led by 11 double-digit gainers.

Celgene Downgraded to Hold at Jefferies

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

Many see the Fed as done for the year. Never assume. Read the words as they are written.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.